CVS Caremark
CVS Caremark is one of the largest pharmacy benefit managers (PBMs) in the United States, managing approximately 27% of all prescription drug claims as of 2024. A subsidiary of CVS Health, Caremark is vertically integrated with Aetna (health insurer) and CVS Pharmacy (retail chain), giving it control over formulary design, pharmacy reimbursement, and prescription fulfillment within a single corporate structure.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-09-25. Score revised 2026-09-25: 74 → 72.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
MedPartners abandoned physician practice management and renamed itself Caremark Rx in September 1999, refocusing on pharmacy benefit management. Caremark was one of a handful of PBMs that a 2003 Connecticut legislative report said controlled most of the market, and rebate and pricing practices were drawing early scrutiny. It did not yet own a pharmacy chain or an insurer, and few documented harms are specific to this period.
The $5.6 billion AdvancePCS merger made Caremark one of the largest PBMs, processing more than 600 million prescriptions a year. ERISA class actions in 2004 accused it of retaining manufacturer rebates and favoring pricier drugs, and a 28-state investigation targeted drug-switch pitches to doctors that raised costs while boosting Caremark's profit (settled for $38.5 million in 2008). Scale was bringing market power and opacity, but Caremark still had no retail pharmacies of its own.
CVS's $21 billion purchase of Caremark created the first major combination of a PBM with a national pharmacy chain. Caremark began steering members to CVS stores through copay differences and the 2009 Maintenance Choice program, prompting NCPA to press the FTC, which closed its probe in 2012 alongside a $5 million settlement over misrepresented Part D prices. A 2008 multistate consent order restricted drug-switching practices, and retroactive Part D DIR fees began their rapid growth around 2010.
Caremark published the first PBM formulary exclusion list in 2012, growing from 34 drugs to 124 by 2016, while the Express Scripts-Medco merger left three PBMs in control of most claims. CVS bought Omnicare and Target's pharmacies, repurchased about $13.3 billion of stock in 2015-2017, imposed retroactive performance-based DIR fees on network pharmacies from 2016, and cut community pharmacy reimbursements in late 2017 while offering to buy struggling stores. Ohio's 2018 audit found PBMs, including Caremark, taking a 31% spread on Medicaid generics.
Closing the $69 billion Aetna deal, cleared after the Justice Department required divestiture of Aetna's individual Part D plans, put an insurer, a PBM and a pharmacy chain under one roof. Federal gag-clause bans took effect just before, but Caremark launched the PrudentRx copay maximizer in 2020, an arbitrator found its variable DIR terms unconscionable in 2021, and a 2026 federal audit later found it overcharged the federal employees' plan $615 million in 2018-2021. Part D pharmacy DIR peaked at $9.5 billion in 2020.
The FTC's June 2022 6(b) orders opened sustained federal scrutiny of PBMs, followed by an FTC antitrust demand to Caremark in December 2023. CVS spent about $18.6 billion on Oak Street Health and Signify Health while cutting about 5,000 jobs, pharmacies sued over DIR fees, Oklahoma acted against steering, and Caremark swapped Humira for biosimilars including its own Cordavis co-brand. It unveiled TrueCost and CostVantage pricing models but lost the Centene contract.
The FTC's September 2024 insulin lawsuit began a period in which Caremark faced enforcement and litigation on almost every front: a CEO change, a House antitrust investigation and report, a $289.9 million False Claims Act judgment, state suits and settlements, a damning Tennessee audit, a $615 million federal audit and a RICO suit. Caremark's July 2025 Zepbound exclusion showed rebate-driven formulary decisions still in force. In 2026 the pressure began producing binding change: federal PBM reform in February, the Zepbound reversal, and a July FTC consent order barring hub interference and changing Caremark's standard offering, while CVS kept fighting state pharmacy-ownership bans in court.
Alternatives
Mark Cuban's transparent-pricing pharmacy sells generics at its cost plus a 15% markup, a $5 pharmacy fee and shipping, with no PBM in the middle of a cash purchase. For many common generics the cash price is lower than a Caremark copay. Ships to all 50 states and can also be used at thousands of affiliated local pharmacies. The catch: the savings are concentrated in generics (brand-name drugs it carries still cost near list price), and cash purchases may not count toward your plan's deductible or out-of-pocket maximum.
Free discount coupons that show cash prices at most U.S. retail pharmacies, often below a PBM copay. Worth checking before every fill: you show the coupon at a participating pharmacy instead of your insurance card. GoodRx has its own data problems (the FTC penalized it in 2023 for sharing users' health data with advertising platforms), and coupon purchases usually don't count toward your insurance deductible, but as a way to sidestep PBM pricing on a specific prescription it is genuinely useful.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (70 events)
Caremark International settles DOJ fraud case for $161 million
Caremark Inc., a subsidiary of Caremark International (a predecessor of the later PBM business), agreed to plead guilty to two criminal informations and pay approximately $161 million in criminal fines, civil restitution and damages. The total included $29 million in criminal fines and roughly $130 million in civil payments to federal and state health programs, over improper payments made to induce doctors and other professionals to refer patients in its home infusion, oncology, hemophilia and human growth hormone businesses. Caremark also agreed to a corporate integrity plan. In a 1996 ruling on the resulting shareholder suit, the Delaware Court of Chancery said Caremark pleaded guilty to mail fraud after an extensive four-year HHS and Justice Department investigation, and that its service contracts with physicians who referred patients had included consultation agreements and research grants.
MedPartners renames to Caremark Rx after PPM collapse
After heavy losses in its physician practice management (PPM) business, MedPartners divested nearly all of its physician practices and announced in September 1999 that it had renamed itself Caremark Rx, refocusing almost entirely on pharmaceutical services and pharmacy benefit management. The company later moved its headquarters from Birmingham, Alabama to Nashville, Tennessee in 2003.
Connecticut legislative research report summarizes scrutiny of PBM rebates and pricing
A Connecticut General Assembly Office of Legislative Research background report on pharmacy benefit managers noted that PBMs managed drug benefits for over 200 million people and that four companies, including Caremark Rx, controlled most of the market. It summarized an ongoing federal Justice Department investigation into PBM rebate arrangements and fees not fully disclosed to clients, formulary decisions favoring more expensive drugs, and drug switching, and noted lawsuits by health plans alleging PBMs kept rebates and discounts rather than passing them on.
Caremark Rx merges with AdvancePCS for $5.6 billion
Caremark Rx completed its merger with AdvancePCS, creating a PBM processing over 600 million prescriptions per year with revenues exceeding $20 billion. AdvancePCS itself was the product of a 2000 merger between PCS Health Systems (founded 1969) and Advance Paradigm. The deal solidified Caremark as one of the largest PBMs nationally.
Caremark Rx hit with ERISA class action over retained rebates
Caremark Rx was served with a putative class action filed by Robert Moeckel on behalf of the John Morrell Employee Benefits Plan in federal court in Tennessee, alleging Caremark acted as an ERISA fiduciary and breached its duties, including by retaining manufacturer rebates and other compensation rather than passing them to plans and by favoring more expensive drugs. Similar suits (Bickley and Dolan) were filed against Caremark in the same period. The lawsuit highlighted the emerging pattern of PBM rebate retention that would intensify over the next two decades.
CVS Corporation acquires Caremark Rx for $21 billion
CVS Corporation merged with Caremark Rx in a $21 billion deal, creating CVS Caremark and combining the largest U.S. retail pharmacy chain with one of the largest PBMs. The merger created the first major vertical integration between a PBM and a retail pharmacy network, enabling CVS to steer prescriptions to its own pharmacies through formulary design and network rules.
Caremark pays $38.5 million to 28 states over drug switching and enters consent order
CVS Caremark agreed to pay $38.5 million to 28 states and D.C. to settle a deceptive-practices suit alleging Caremark told doctors that switching patients to certain brand-name drugs would save money when the switches often saved little or raised costs while increasing Caremark's profits, and that it kept rebates that should have gone to employers and patients. The accompanying consent order restricts drug-switch requests and governs Caremark's dealings with clients, manufacturers, pharmacies, plan members and prescribers.
NCPA presses FTC to investigate CVS Caremark steering
The National Community Pharmacists Association met with FTC Chairman Jon Leibowitz to press the agency to re-examine the 2007 CVS-Caremark merger, having pushed for an FTC review since a December 2008 letter. The Wall Street Journal reported that CVS Caremark was apparently steering its pharmacy benefit patients to its own drugstores by raising co-payments for some who filled prescriptions elsewhere, and its Maintenance Choice program limited 90-day maintenance fills to CVS stores or Caremark mail order. In July 2009 Senate testimony, NCPA said more than 80 independent pharmacists and several patients attended the May 13 FTC meeting. It cited a patient whose monthly copay rose from about $5 to $50 after letters told her to pay a 'penalty co-pay' or move her prescriptions to CVS retail or Caremark mail order, and alleged that CVS pharmacists were told through Caremark's system when members used other pharmacies.
DIR fees begin rapid growth as PBM extraction mechanism
Pharmacy DIR (direct and indirect remuneration) fees in Medicare Part D began their explosive growth around 2010. According to CMS data, pharmacy price concessions grew more than 107,400% between 2010 and 2020, from about $8.9 million to $9.5 billion. PBMs including CVS Caremark introduced performance-based network fees assessed retroactively against pharmacies, creating an unpredictable financial burden and one of the largest PBM extraction mechanisms.
FTC closes CVS Caremark antitrust investigation without action
The FTC closed its investigation into CVS Caremark's post-merger marketing and steering practices without enforcement action, despite complaints from pharmacists, trade groups, and members of Congress. The closure letter came alongside a $5 million settlement over misrepresented Medicare Part D drug prices, which Akin Gump described as closing the probe 'under cover' of that settlement.
Express Scripts completes $29 billion Medco merger
Express Scripts acquired Medco Health Solutions in a $29 billion deal that combined two of the three largest PBMs, alongside CVS Caremark. The FTC closed its investigation on April 2, 2012, even though the merged firm's market share would be just over 40%, which critics later cited as a regulatory failure that enabled PBM consolidation.
CVS Caremark introduces first formulary exclusion list
Caremark became the first PBM to publish a formulary exclusion list, removing 34 drugs from its standard national formulary. The practice forced patients on stable medications to switch to Caremark-preferred alternatives based on rebate economics rather than clinical need. The exclusion list grew to 95 products by 2015 and 124 by 2016, and was adopted industry-wide by competing PBMs.
CVS Caremark authorizes $6 billion stock buyback program
CVS Caremark's board approved a new share repurchase program of up to $6 billion, to be completed over several years. The company had $3 billion left under its prior authorization at the start of 2012 and bought back 26.6 million shares for about $1.2 billion in the second quarter of 2012 alone.
CVS Health acquires Omnicare for $12.9 billion
CVS Health completed its acquisition of Omnicare, the leading provider of pharmacy services to long-term care facilities, for a total enterprise value of approximately $12.9 billion. The deal gave CVS control of nursing home prescription dispensing, further concentrating pharmacy market power. In 2022 CVS said the long-term care business was 'no longer a strategic asset' and moved to sell it.
CVS acquires Target's 1,672 pharmacies and clinics for $1.9 billion
CVS Pharmacy completed acquisition of Target Corporation's pharmacy and clinic businesses for $1.9 billion, adding 1,672 pharmacy locations and 79 clinic locations across 47 states. The deal eliminated a significant independent pharmacy channel and concentrated more prescription volume under CVS's integrated PBM-pharmacy umbrella.
CVS Caremark begins performance network fees for independent pharmacies
Beginning in 2016, after a CMS rule change let contingent price concessions be excluded from the point-of-sale price, CVS Caremark required Part D network pharmacies, including independents, to take part in performance programs and pay retroactive DIR fees based on performance metrics, some outside the pharmacy's control. These fees were clawed back months after prescriptions were dispensed, destabilizing independent pharmacy finances.
CVS Health repurchases about $13.3 billion of stock from 2015 to mid-2017
Between 2015 and mid-2017, CVS Health repurchased approximately $13.3 billion of its own stock, including about $4.75 billion in 2015 and about $4.6 billion in 2016. The buybacks came as the company was expanding DIR fee collections from pharmacies. According to CVS's 2017 10-K, the repurchases ran under a $10 billion program authorized in December 2014, completed in 2017, and a $15 billion program authorized in November 2016.
CVS Caremark cuts pharmacy reimbursements, then offers to buy struggling competitors
Starting in late October 2017, around the time CVS was preparing its Aetna deal, CVS Caremark sharply cut reimbursements to community pharmacies in Ohio, Arkansas, Iowa, New Jersey, New York and possibly other states, in some cases below pharmacists' costs. At the same time, CVS sent letters to pharmacies citing their likely financial problems from declining reimbursements and offering to buy them out.
CVS Health announces $69 billion Aetna acquisition
CVS Health announced it would acquire health insurer Aetna for approximately $207 per share ($145 in cash plus 0.8378 CVS shares), about $69 billion, or $77 billion including assumed debt. The deal, which CVS called the biggest health care merger in U.S. history, was designed to create a vertically integrated entity controlling insurance, PBM, retail pharmacy, mail-order, and specialty pharmacy in one corporate structure.
Ohio audit finds PBMs took a 31% spread on Medicaid generics
Ohio Auditor Dave Yost reported that PBMs in Ohio's Medicaid managed care program, among them CVS Caremark, kept spreads of about $224.8 million in the year to March 2018, including $208 million (31.4%) on generic prescriptions, and that the PBMs' lack of information limited the review. CVS said the spread model was chosen by the plans and that it passed through all government-mandated rebates. Ohio ordered its plans to end spread-pricing contracts by January 1, 2019.
Federal gag clause ban signed into law
President Trump signed the Know the Lowest Price Act and the Patient Right to Know Drug Prices Act, banning PBM and insurer gag clauses that had prevented pharmacists from telling patients when paying cash would cost less than their insurance copay. Such clauses in PBM-pharmacy contracts could leave patients paying more than necessary.
DOJ clears CVS-Aetna merger on condition Aetna sells its Part D plans
The Justice Department and five state attorneys general settled their antitrust challenge to the $69 billion CVS-Aetna merger by requiring Aetna to divest its individual Medicare Part D prescription drug plan business to WellCare. The remedy addressed overlap in Part D plans only; it left the combination of insurer, PBM and pharmacy chain intact.
CVS Health completes $69 billion Aetna acquisition
CVS Health closed its acquisition of Aetna, creating the most vertically integrated healthcare company in U.S. history. A single prescription fill could now generate revenue across Aetna (premiums), Caremark (spread pricing and fees), and CVS Pharmacy (dispensing). The deal locked employers into multi-product relationships where switching any single component disrupted the entire system.
CVS Caremark launches PrudentRx copay maximizer program
CVS Caremark launched the PrudentRx Copay Optimization Program, a copay maximizer run through an exclusive partnership with a newly formed private company. Maximizers capture the full value of manufacturer copay assistance for specialty drugs to reduce plan costs, and Drug Channels noted such programs require patients to affirmatively enroll or face much higher costs and can pay intermediaries fees tied to the manufacturer's assistance.
CVS Health exposes 1 billion records in unsecured database
A cybersecurity researcher discovered an unsecured CVS Health cloud database containing over 1 billion search records, including customer email addresses, prescription queries, and other medical search metadata. The database was not password protected and had been accessible online since at least March 2021. The breach highlighted lax data governance despite CVS processing sensitive health information for hundreds of millions of Americans.
Arbitrator orders Caremark to repay AIDS Healthcare Foundation nearly $23 million in DIR fees
An arbitrator ruled for the AIDS Healthcare Foundation in its DIR fee dispute with Caremark, finding the variable, performance-based DIR provisions calculated at Caremark's discretion unconscionable and unenforceable, and ordered Caremark to pay about $22 million in DIR fees plus costs, nearly $23 million in all. A federal court in Arizona confirmed the award in September 2022. It was one of the first major wins for a pharmacy challenging PBM DIR fees.
FTC launches 6(b) inquiry into the six largest PBMs
The Federal Trade Commission launched an inquiry into the PBM industry, sending compulsory Section 6(b) orders to the six largest PBMs, including CVS Caremark, requiring information and records about their business practices. The study focused on how vertically integrated PBMs affect the access and affordability of prescription drugs, including pharmacy reimbursement and patient access.
New York Attorney General sues CVS over 340B anticompetitive scheme
The New York Attorney General filed suit alleging CVS forced safety net hospitals and health care providers in the federal 340B Drug Pricing Program to purchase administrative services from CVS subsidiary Wellpartner as a condition for contracting with CVS pharmacies. The lawsuit claimed this forced bundling leveraged CVS's market position to extract fees from hospitals serving vulnerable populations.
CVS announces $10.6 billion Oak Street Health acquisition
CVS Health announced it would acquire Oak Street Health, a primary care company with 169 medical centers, for about $9.5 billion in cash ($10.6 billion including debt). Combined with the $8 billion Signify Health acquisition (completed March 2023), CVS spent about $18.6 billion extending its vertical integration into primary care and home health services, giving it unprecedented control over the full patient journey from diagnosis through prescription fulfillment.
New York judge dismisses AG's 340B tying suit against CVS
A New York state judge dismissed without prejudice the Attorney General's antitrust suit alleging CVS forced 340B covered entities to use its Wellpartner administrator, finding CVS lacked power to coerce them because most New York covered entities did not contract with any CVS pharmacy.
Oklahoma Insurance Department files action against CVS Caremark for patient steering
Oklahoma Insurance Commissioner Glen Mulready filed a notice of hearing and order to show cause against CVS Caremark alleging violations of the state's Patient's Right to Pharmacy Choice Act, citing more than 100 complaints that claims from Oklahoma pharmacies were denied and patients told to fill prescriptions at CVS. The order tied the denials to a Caremark program for self-funded plans requiring 90-day maintenance fills by CVS mail order or at CVS retail pharmacies.
Caremark restores 90-day options for Oklahoma members after state action
Following the Oklahoma Insurance Department's steering action, Caremark put in place a plan letting affected clients reinstate 90-day and mail-order benefits for Oklahoma members; the department expected 79% of members of clients electing the fix to have 90-day mail access by July 31, 2023.
CVS Health cuts about 5,000 jobs in cost-cutting drive
CVS Health eliminated about 5,000 jobs, mostly non-customer-facing corporate roles, as part of a restructuring aimed at cutting up to $800 million in costs in 2024. The layoffs came while the company was spending about $18.6 billion on the Oak Street Health and Signify Health acquisitions, illustrating a pattern of worker cuts to fund corporate expansion and shareholder returns.
Pharmacies file class action against CVS Caremark for DIR fee clawbacks
Osterhaus Pharmacy filed a class action against CVS Health, Caremark and Aetna seeking to recover DIR fees collected from independent pharmacies. The suit alleged Caremark conditioned access to its Medicare Part D network on accepting a second transaction involving performance fees, using its position as the largest PBM, with a third or more of the market, as leverage to force pharmacies into these arrangements.
CVS pharmacists walk out over unsafe working conditions
CVS pharmacists in the Kansas City area walked off the job to protest understaffing and working conditions, forcing at least a dozen stores to close. Protesters said CVS had cut technician hours even as prescription and vaccine demand grew; one pharmacist said they worked alone for most of the 64 hours a week their store was open. CVS promised more paid hours, more staff and lower vaccination goals, and pharmacists' associations in Nebraska, Iowa and California voiced support, citing the national Pharmacy Workplace and Well-Being Report. USA Today reported that nearly two dozen pharmacists took part in the first walkout, and one said the workload and staffing left her unable to go to the bathroom during her 10-hour shift.
Three-day nationwide pharmacy staff walkout hits CVS and Walgreens
A broader three-day walkout by pharmacy staff at CVS and Walgreens stores nationwide drew attention to systemic understaffing across the retail pharmacy industry. The action followed the September Kansas City walkout and the National Pharmacy Workplace and Well-Being Report documenting persistent issues of inadequate staffing, unreasonable metrics, and workplace harassment. CVS subsequently vowed to improve working conditions.
CVS announces CostVantage and TrueCost transparency pricing models
CVS Health unveiled two new pricing models amid scrutiny of high drug prices: CostVantage, under which its pharmacies would be reimbursed on a transparent formula of drug cost plus a set markup plus a patient management fee (launching with commercial payers in 2025), and Caremark's TrueCost, offering clients pricing based on the net cost of drugs with visibility into administrative fees. CNN reported that some experts were skeptical CostVantage would help patients, since it would not directly change what they pay at the counter and the markups and fees would not be made public.
CVS Caremark loses Centene's $35 billion PBM contract to Express Scripts
Express Scripts began servicing approximately 20 million Centene beneficiaries after winning the contract away from CVS Caremark. The loss caused CVS Caremark's 30-day equivalent claims to fall 18.2%, from 2.3 billion in 2023 to 1.9 billion in 2024, dropping its market share from 34% to 27%. Express Scripts overtook CVS Caremark as the leading PBM by claims volume.
Caremark drops Humira from main formularies in favor of biosimilars including its own Cordavis co-brand
CVS Caremark announced it would remove Humira from its major national commercial formularies on April 1, 2024 and cover adalimumab biosimilars instead, including a co-branded Humira supplied by AbbVie to CVS's Cordavis subsidiary and Sandoz's Hyrimoz under a Cordavis private label. Patients were switched for cost reasons, and the move put CVS-affiliated products in preferred positions on its own formulary.
FTC interim report exposes PBM pricing markups and specialty steering
The FTC's first interim staff report found that pharmacies affiliated with Big 3 PBMs received 68% of specialty drug dispensing revenue in 2023, up from 54% in 2016. The report identified PBM pricing opacity as a central concern and documented how spread pricing, rebate retention, and formulary manipulation inflated drug costs for patients and plan sponsors. It specifically named CVS Caremark as one of the three firms dominating the market.
FTC sues CVS Caremark over anticompetitive insulin pricing
The Federal Trade Commission filed suit against the three largest PBMs, including CVS Caremark and its affiliated GPO Zinc Health Services, for artificially inflating insulin list prices through a rebate system that prioritized high rebates over low patient costs. The FTC alleged the Big 3 PBMs abused their economic power to rig pharmaceutical supply chain competition, forcing patients with deductibles and coinsurance to pay more than the actual net cost of their insulin.
CVS Health lays off 2,900 amid reports of a possible breakup
CVS Health announced about 2,900 layoffs, roughly 1% of its workforce and mostly corporate roles, as part of the $2 billion cost-cutting plan unveiled that summer, while Reuters and others reported its board was weighing a strategic review including a possible breakup of its retail, insurance and PBM businesses. Activist investor Glenview Capital met with CVS leadership around the same time, but said press reports that it was pushing for a breakup were false.
CEO Karen Lynch forced out, replaced by Caremark chief David Joyner
CVS Health CEO Karen Lynch stepped down after the stock lost 19% of its value in 2024 amid rising Aetna claims costs and operational challenges. She was replaced by David Joyner, who had led CVS Caremark as its president. Lynch earned $23.4 million in 2024 despite the company's declining performance, while Joyner earned $17.8 million for his partial-year appointment.
Activist Glenview Capital wins four CVS board seats
Weeks after ousting CEO Karen Lynch, CVS Health gave activist investor Glenview Capital four board seats, expanding the board to 16, amid a strategic review and a multibillion-dollar cost-cutting drive.
House Judiciary Committee launches antitrust investigation of CVS Caremark
House Judiciary Committee Chairman Jim Jordan and Rep. Thomas Massie, chair of its antitrust subcommittee, opened an investigation into CVS Caremark for potential antitrust violations, questioning whether it used the threat of network exclusion to stop independent pharmacies from working with companies that bypass PBM networks. The committee requested documents from CVS Health.
FTC second interim report finds $7.3 billion in PBM specialty drug markups
The FTC's second interim staff report analyzed specialty generic drugs dispensed 2017-2022 and found the Big 3 PBMs' affiliated pharmacies generated over $7.3 billion in dispensing revenue above estimated acquisition cost on specialty generics, plus $1.4 billion from spread pricing. Markups of hundreds to thousands of percent were documented on drugs treating cancer, HIV, and other serious conditions.
Federal court orders CVS Caremark to comply with FTC document demands
The U.S. District Court for the District of Columbia ordered CVS Caremark to comply with an FTC civil investigative demand issued in December 2023 in an antitrust investigation of its conduct in managing its pharmacy network, after CVS had tried to delay and quash the demand.
Arkansas enacts first state ban on PBM pharmacy ownership
Arkansas enacted Act 624, the first state law prohibiting PBMs from owning or operating pharmacies. The law directly targeted CVS Health's vertical integration model, as CVS operated 23 pharmacies in the state. CVS and Cigna's Express Scripts filed federal lawsuits to overturn the law in May 2025, and a federal judge issued a preliminary injunction blocking enforcement in July while litigation proceeded.
Rhode Island attorney general sues Caremark and Zinc over rebate scheme
Rhode Island Attorney General Peter Neronha sued CVS Caremark, Express Scripts and OptumRx and their rebate aggregators, including CVS's Zinc, in state Superior Court, alleging they profit from rising drug prices while branding themselves as cost savers. CVS called the claims inaccurate and misleading.
North Carolina state health plan accuses Caremark of withholding rebates
North Carolina's Treasurer said negotiations with CVS Caremark, PBM for the 750,000-member State Health Plan, had stalled and that the company owed the state tens of millions of dollars and was trying to rewrite the contract to avoid repaying it; the plan considered legal action. The dispute was settled in October 2025 with additional reporting requirements.
CVS Caremark ordered to pay $95 million in Medicare Part D fraud verdict
Following an eight-day bench trial, Judge Mitchell Goldberg ruled that Caremark inflated Medicare Part D drug prices to offset other costs in its pricing arrangements, while finding the case did not prove liability against CVS Health or CVS Pharmacy. The whistleblower, Sarah Behnke, a former actuary at CVS's Aetna subsidiary, filed the False Claims Act case in 2014, alleging Caremark overcharged Medicare between 2010 and 2016. The court found $95 million in single damages.
Caremark drops Zepbound from its main formulary after Wegovy deal
CVS Caremark stopped covering Eli Lilly's Zepbound on its most common formulary template, covering 25-30 million people, and preferred Novo Nordisk's Wegovy. Letters told patients the alternative 'may cost less' and that refills after July 1 would be at full cost. Patients and doctors objected that the drugs are not interchangeable.
CVS Caremark hit with $290 million final judgment in Medicare fraud case
Judge Goldberg entered a final judgment of $289.9 million against CVS Caremark in the Behnke whistleblower case, tripling the $95 million damages under the False Claims Act and adding $4.9 million in civil penalties. The judge stated Caremark's conduct 'broke CMS's trust, and as a result, the public's trust in CMS.' CVS announced it would appeal.
Patients file class action over Caremark's Zepbound exclusion
Health plan members filed a proposed class action against CVS Caremark over its refusal to cover Zepbound after its Wegovy arrangement with Novo Nordisk. CNN reported one patient's care team submitted dozens of letters amid repeated appeal denials. In August 2026 a federal judge in New York let the case proceed, finding the plaintiffs had validly alleged self-dealing.
Caremark pays Oklahoma $32.1 million over retained state employee plan rebates
CVS Caremark agreed to pay $32.1 million to settle Oklahoma's claim that it kept manufacturer rebates and discounts owed to the HealthChoice state employee plan from January 2020 through December 2024, and to report collected rebates quarterly. Caremark denied wrongdoing.
North Carolina and Caremark settle State Health Plan contract dispute
North Carolina's Treasurer announced an agreement with CVS Caremark securing what it called hundreds of millions of dollars for the State Health Plan, with added reporting requirements and plan control over its formulary.
Oklahoma reaches $5 million settlement with CVS Caremark for pharmacy underpayments
Oklahoma Attorney General Gentner Drummond announced a $5 million settlement with CVS Caremark resolving allegations that the PBM paid pharmacies less than their actual drug acquisition costs for 68,099 prescriptions filled between January 2024 and August 2025. The settlement required CVS Caremark to implement reforms including reviewing payment disputes against national cost benchmarks and responding to disputes within 10 days.
House Judiciary report concludes CVS may have violated federal antitrust laws
The House Judiciary Committee's Antitrust Subcommittee released an interim report finding that CVS Caremark 'weaponized audits and cease-and-desist letters' to prevent independent pharmacies from working with competing digital pharmacy hubs. Internal documents showed CVS changed network rules specifically to suppress competition, and CVS provided no evidence supporting its fraud justification. Exclusion from Caremark's network could prevent a pharmacy from serving nearly one-third of insured Americans.
PBM Reform Act signed into law as part of federal spending bill
President Trump signed the Consolidated Appropriations Act of 2026, which included key provisions of the PBM Reform Act of 2025 — the first major federal PBM reform in decades. The law separates PBM compensation in Medicare Part D from drug prices and rebates, addressing a core mechanism through which PBMs like Caremark extracted value from the pharmaceutical supply chain.
Warren-Hawley Break Up Big Medicine Act targets PBM vertical integration
Senators Elizabeth Warren and Josh Hawley introduced the Break Up Big Medicine Act, which would force structural separation of healthcare conglomerates that own combinations of insurers, PBMs, pharmacies and provider businesses. Companies would have one year after enactment to comply, with automatic penalties including disgorgement of profits and forced asset sales, and enforcement by federal agencies and state attorneys general. The bill directly targets CVS Health's corporate structure.
Tennessee audit reveals widespread CVS Caremark PBM violations
The Tennessee Department of Commerce and Insurance audit found 11 formal findings and 5 observations documenting widespread PBM violations by CVS Caremark. Key findings included reimbursement disparities up to 16,510% between affiliated and non-affiliated pharmacies, continued spread pricing in contracts entered after Tennessee's ban, failure to pay required dispensing fees in 21.7% of tested claims, and denial of 27.9% of appeals without giving pharmacies the legally required response window.
Louisiana settles three suits with CVS and Caremark for $45 million
Louisiana's attorney general settled three 2025 lawsuits against CVS Health and Caremark for $45 million without admission of liability. The suits concerned CVS's use of customer information for a mass text campaign against a 2025 bill that would have barred PBMs from owning pharmacies (the bill was shelved), its vertical integration, and unfair practices against independent pharmacies.
Federal audit finds Caremark overcharged federal employees' plan $615 million
The OPM Inspector General found CVS Caremark overcharged the Blue Cross Blue Shield Federal Employee Program $615.1 million for 2018-2021, including $478.7 million in negotiated discounts with two large retail chains not passed through, $108.6 million in transmission-fee credits not returned, and $27.8 million in excess incentive payments. CVS called it a retroactive contract dispute.
RICO class action accuses Caremark of selling formulary access through Zinc
A roofers' union welfare trust filed a proposed class action alleging CaremarkPCS and CVS Health violated RICO and breached client contracts by extracting billions in payments from drug makers through the Zinc Health Services subsidiary, described as fees, in exchange for formulary access instead of passing savings to clients. The case was later transferred to the Northern District of Illinois.
Ninth Circuit sends pharmacies' DIR fee claims against Caremark to arbitration
The Ninth Circuit affirmed an order compelling four independent pharmacies to arbitrate their antitrust claims over Caremark's Medicare Part D fees under Caremark's standard provider agreement. The district court had struck three provisions of that arbitration clause as unconscionable before enforcing the rest.
CVS sues Tennessee hours after it bans PBMs from owning pharmacies
Tennessee enacted the FAIR Rx Act, the second state ban on PBMs owning pharmacies, which effectively targets CVS as the only company there with both. After a spring ad campaign and warnings that it would have to close all 134 Tennessee stores, CVS sued the same day in federal court, arguing the law is unconstitutional and preempted.
Caremark reverses course and restores Zepbound coverage
After patient backlash and litigation, CVS Caremark said Zepbound would return to its standard formulary (about 25-30 million people) by October 1, 2026, and Lilly's oral drug Foundayo would be added. Employers still decide whether to cover weight-loss drugs.
Florida attorney general opens antitrust investigation into CVS and Caremark
Florida's attorney general issued a civil investigative demand to CVS Health examining whether Caremark steers patients to CVS stores, pays affiliated pharmacies more than independents for identical prescriptions, uses burdensome audits and restrictive contracts, and contributes to pharmacy deserts.
FTC settles insulin case with Caremark and bars interference with pharmacy hubs
The FTC's proposed consent order resolving its insulin rebate case requires Caremark and Zinc to stop disfavoring low-list-price drugs on standard formularies, offer point-of-sale rebate pass-through and an option to leave spread pricing and rebate guarantees, delink manufacturer fees from list prices, cap insulin costs, offer community pharmacies new terms, and stop interfering with pharmacies' use of hub services under a monitor. The FTC estimated up to $8.5 billion in savings over 10 years; the deal carries no monetary penalty and CVS said it resolves all outstanding FTC matters.
Florida sues insulin makers and Big 3 PBMs, including Caremark and Zinc
Florida's attorney general filed an antitrust and deceptive-practices suit in Miami-Dade County against Eli Lilly, Novo Nordisk, Sanofi, CVS Caremark, Express Scripts, OptumRx and rebate aggregators including Zinc, alleging list prices for insulin and related diabetes drugs were inflated in exchange for rebates and preferred formulary placement.
Evidence (59 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (10 entries)
Orchestrator fix: $95M verdict item said the court found inflated cost data 'dating back to 2010'; per Healthcare Dive, 2010-2016 was the period Behnke alleged, not a court finding. Reworded to match the source.
Checked 2 alternatives. Cost Plus Drugs: false 'does not cover brand-name medications' corrected, pricing formula updated ($5 pharmacy fee + shipping), affiliate pharmacies added. GoodRx: stripped typed-in score, added deductible caveat.
Checked 22 removed/trimmed claims: 1 restored, 6 partly restored, 15 confirmed removed, 0 already present. Restored: eight-day Behnke bench trial (court final-judgment opinion). Partly: 1995 mail fraud plea/four-year probe/research grants (Del. Ch. 1996); 80+ pharmacists at FTC meeting and $5-to-$50 penalty copay (NCPA Senate testimony 2009); $10B 2014 buyback program (CVS FY2017 10-K); walkout bathroom account, nearly two dozen pharmacists (USA Today 2023); CostVantage expert skepticism (CNN 2023); Glenview meetings with breakup denial (Fierce 2024). Added evidence: Del. Ch. 1996 opinion (d10), NCPA 2009 testimony (d6), USA Today 2023 (d9). Confirmed removed: 1998 MAC event, 2005 formulary, 2006 technicians/600M scripts (10-K shows ~520M), 2011 labor standards, 2014 specialty 20-40% margins (timeline and evidence), 2017 buyout-letter 'times were hard' quote and store closures, Caremark gag clauses (Caremark said it did not use them), FTC 'emboldened' critique, 7-8 independents/day (NCPA says 1+/day), 10-20x generic spread, 6-12 month switching, $40B DIR, 'near minimum wage', 27 pharmacists / 400-500 scripts per shift.
Checked 97 items + prose. 33 verified, 32 corrected (5 date-only), 26 re-sourced, 6 removed. Invented: '$9B (2015) to $40B+ (2023)' DIR figures; '20-40% vs 1-2%' specialty/generic margins; Warren-Hawley bill '10% of profits in escrow' and 'divestiture trustees'; a '2022 cyberattack' on CVS. Major fixes: NY AG suit dated 2022 not 2024; Oklahoma action 2023 not 2024; AHF award was arbitration; MedPartners rename 1999; 2010 buyback was the 2012 $6B program; layoffs double-counted; Glenview not pushing breakup; FTC 6(b) study conflated with 2025 CID order.
Since Feb 2026: federal PBM reform enacted (Feb 3); Louisiana $45M settlement (Feb 20); OPM OIG audit found $615M FEHBP overcharges 2018-21 (Mar 13); RICO class action over Zinc fees (Mar 19); Ninth Circuit sent Osterhaus DIR claims to arbitration (May 15); Tennessee banned PBM pharmacy ownership and CVS sued (May 22); Zepbound coverage reinstated from Oct 1 (May 28); Florida CID (Jun 23) and insulin antitrust suit (Sep 24); FTC insulin settlement with hub-interference ban and no money (Jul 14); no buybacks, CEO $21.2M (336:1). 74->72. D6 7->6 (recalibration: Caremark-specific evidence is maximizer, steering, switch letters; 'buried opt-out/fax-only' claims unsourced, fits 4-6/6 not 7), D8 9->8 (recalibration: 27% share with strong rivals and no antitrust liability finding; active investigations and self-preferencing fit 8, not near-monopoly 9). Others held: D1 7 (Zepbound exclusion in force until Oct 1; reversal and insulin cap not yet effective), D3 7, D10 8. D7 summary drops unsourced IQVIA data-sales claim. Trajectory worsening->stable (binding FTC/federal reforms and Zepbound reversal vs. new audits, suits and CVS litigation against state laws). Eras: 'Early PBM Era' re-dated 2000-01-01->1999-09-13 (Caremark Rx rename) and relabeled 'Standalone Caremark Rx', and split at 2004-03-24 (AdvancePCS merger) -> new 'AdvancePCS Scale-Up'; 'CVS Merger & Vertical Integration' re-dated 2007-03-01->2007-03-22 (merger); 'Triopoly Consolidation' kept at 2012-07-01, relabeled 'Formulary Exclusion Era'; 'Aetna Mega-Merger' re-dated 2018-11-01->2018-11-28 (close); 'Post-Integration Extraction' re-dated 2022-06-01->2022-06-07 (FTC 6(b)) and relabeled 'FTC Scrutiny Begins'; 'Regulatory Siege' re-dated from assessment date 2026-02-15 to 2024-09-20 (FTC insulin suit). Timeline[6] updated: 2008 consent order merged with its $38.5M 28-state drug-switching settlement, dated 2008-02-14, ranitidine/CIA retail detail dropped.
Triaged 2026-06-29; no rescore warranted (no material change since baseline, or changes sub-threshold).
Fixed market share: 33% -> 27% (lost Centene contract in 2024, per Drug Channels). Fixed history format (non-standard fields -> score/source). Removed incorrect '30% PBM market share' from D8 summary.